Dabbs Rebecca A, Wilson Mark R
Illawarra Health and Medical Research Institute, School of Biological Sciences, University of Wollongong, Wollongong, New South Wales, Australia.
PLoS One. 2014 Jan 23;9(1):e86989. doi: 10.1371/journal.pone.0086989. eCollection 2014.
Clusterin was the first described secreted mammalian chaperone and is implicated as being a key player in both intra- and extracellular proteostasis. Its unique combination of structural features and biological chaperone activity has, however, previously made it very challenging to express and purify the protein in a correctly processed and chaperone-active form. While there are multiple reports in the literature describing the use of recombinant clusterin, all of these reports suffer from one or more of the following shortcomings: details of the methods used to produce the protein are poorly described, the product is incompletely (if at all) characterised, and purity (if shown) is in many cases inadequate. The current report provides the first well validated method to economically produce pure chaperone-active recombinant clusterin. The method was developed after trialling expression in cultured bacterial, yeast, insect and mammalian cells, and involves the expression of recombinant clusterin from stably transfected HEK293 cells in protein-free medium. The product is expressed at between 7.5 and 10 µg/ml of culture, and is readily purified by a combination of immunoaffinity, cation exchange and size exclusion chromatography. The purified product was shown to be glycosylated, correctly proteolytically cleaved into α- and β-subunits, and have chaperone activity similar to that of human plasma clusterin. This new method creates the opportunity to use mutagenesis and metabolic labelling approaches in future studies to delineate functionally important sites within clusterin, and also provides a theoretically unlimited supply of recombinant clusterin which may in the future find applications in the development of therapeutics.
凝聚素是最早被描述的分泌型哺乳动物伴侣蛋白,被认为是细胞内和细胞外蛋白质稳态的关键参与者。然而,其独特的结构特征和生物伴侣活性组合,使得以前很难以正确加工且具有伴侣活性的形式表达和纯化该蛋白。虽然文献中有多篇报道描述了重组凝聚素的使用,但所有这些报道都存在以下一个或多个缺点:用于生产该蛋白的方法细节描述不佳,产品(如果有的话)表征不完整,并且在许多情况下纯度(如果显示)不足。本报告提供了第一种经过充分验证的方法,可经济地生产纯的具有伴侣活性的重组凝聚素。该方法是在对培养的细菌、酵母、昆虫和哺乳动物细胞中的表达进行试验后开发的,涉及在无蛋白培养基中从稳定转染的HEK293细胞中表达重组凝聚素。产物的表达量为每毫升培养物7.5至10微克,并且通过免疫亲和、阳离子交换和尺寸排阻色谱法的组合很容易纯化。纯化后的产物显示出糖基化,经蛋白水解正确切割成α和β亚基,并且具有与人血浆凝聚素相似的伴侣活性。这种新方法为未来研究中使用诱变和代谢标记方法来确定凝聚素内功能重要位点创造了机会,并且还提供了理论上无限量的重组凝聚素,未来可能会在治疗药物开发中得到应用。